Mease PJ, Kellner H, Morita A, et al. Efficacy and Safety Results from a Phase 2 Trial of Risankizumab, a Selective IL-23p19 Inhibitor, in Patients with Active Psoriatic Arthritis. ACR 2017, abstract 2L.
JAK-remmers en acne: een systematische review en meta-analyse
dec 2023 | Arthritis psoriatica, Eczeem, IBD, Psoriasis, RA, SLE